Solid tumor biotech Silverback Therapeutics ups proposed deal size by 56% ahead of $195 million IPO

Solid tumor biotech Silverback Therapeutics ups proposed deal size by 56% ahead of $195 million IPO

Submitted by admin on December 3, 2020 - 11:00am
Source: 
NASDAQ
News Tags: 
IPOs
Silverback Therapeutics
solid tumors
Headline: 
Solid tumor biotech Silverback Therapeutics ups proposed deal size by 56% ahead of $195 million IPO
snippet: 

Silverback Therapeutics, a Phase 1 biotech developing TLR8 agonist-antibodies for HER2/3 solid tumors, raised the proposed deal size for its upcoming IPO on Thursday.

Do Not Allow Advertisers to Use My Personal information